# A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

> **NCT06259552** · PHASE1 · RECRUITING · sponsor: **SparX Biotech(Jiangsu) Co., Ltd.** · enrollment: 232 (estimated)

## Conditions studied

- Solid Tumor
- HNSCC
- RCC
- CRC

## Interventions

- **BIOLOGICAL:** SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody

## Key facts

- **NCT ID:** NCT06259552
- **Lead sponsor:** SparX Biotech(Jiangsu) Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06259552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06259552, "A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06259552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*